anthracycline


Also found in: Wikipedia.

anthracycline

 [an″thrah-si´klēn]
a class of antibiotics isolated from cultures of Streptomyces peucetius; it includes the antineoplastic agentsdaunorubicin and doxorubicin. The use of these drugs is limited by a chronic, cumulative, dose-related toxicity resulting in irreversible congestive heart failure.
Anthracycline. For daunorubicin, R1 = -CH3; for doxorubicin, R1 = -CHOH.

an·thra·cyc·line

(an'thra-sīk'lin, -lēn),
Anticancer agent consisting of three moieties: a pigmented aglycone, an amino sugar, and a lateral chain. Examples include doxorubicin, daunorubicin, and daunomycin (pirubicin).

anthracycline

/an·thra·cy·cline/ (-si´klēn) a class of antineoplastic antibiotics produced by Streptomyces peucetius and S. coeruleorubidus, including daunomycin and doxorubicin.
Enlarge picture
Anthracycline. For daunorubicin, R1=sbondCH3; for doxorubicin, R1=sbondCHOH.

anthracycline

Oncology A chemotherapeutic used in leukemia to prevent cell division Adverse effects Dose-dependent stomatitis, N&V and BM suppression which 'maxes' at ± 10 days; alopecia is normal; extravasation at IV injection site causes severe, protracted ulcers and necrosis. See Chemotherapy, Daunorubicin, Doxorubicin, Idarubicin.

anthracycline

a class of antibiotics isolated from cultures of Streptomyces peucetius; it includes the antineoplastic agents daunomycin and doxorubicin. See also anthracycline antibiotic.
References in periodicals archive ?
The product is an oncology support drug that prevents chronic cumulative cardiotoxicity caused by high dose anthracycline chemotherapy.
Totect is an emergency oncology intervention, which is indicated to reverse the toxic effects of anthracycline chemotherapy in case of extravasation.
Annamycin is an anthracycline intended for the treatment of relapsed or refractory AML.
National Institute for Health and Clinical Excellence (NICE) as a treatment for patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for advanced disease (prior therapy may have included an anthracycline or a taxane, and capecitabine) in NICE's Final Appraisal Determination (FAD).
The team also found that dexrazoxane has proven helpful in preventing many of the cardiotoxic effects of anthracycline treatment, without reducing its anticancer effects.
In order to provide optimal treatment to this subpopulation of cancer patients with hypertension comorbidity, it is necessary to understand the potential effects of hypertension and anthracycline treatment on short- and long-term cardiac function.
Due to their broad antineoplastic activity, anthracycline are the most widely used agents in oncological practice.
The exact mechanism of anthracycline related cardiomyopathy is poorly understood a commonly accepted theory involves myocardial damage caused by mitochondrial injury and free radical formation2.
Past clinical trials in younger, healthier women showed improved survival, but also increased heart complications linked to trastuzumab, especially when combined with a frequently used therapy called anthracycline chemotherapy.
Reviewing literature we find that several risk factors have been mentioned for cardiotoxicity of anthracyclines; these risk factors include: the cumulative anthracycline dose, length of post-therapy interval, rate of anthracycline administration, individual anthracycline dose, type of anthracycline, concomitant radiation therapy, concomitant other chemotherapy agents, pre-existing cardiac risk factors, comorbidities, age, sex, and genetic factors [5-12].
The study also found that a regimen without the thug Adriamycin, an anthracycline commonly used to treat breast cancer but one that, especially when paired with Herceptin, can cause permanent heart damage, was comparable to a regimen with Adriamycin.
Cardiomyopathy which develops with combined use of radiotherapy and anthracycline group medications is one of these problems.